Home / Street Sector / Active Movers in Hot Line- T-Mobile US (NASDAQ:TMUS), Amarin Corporation (NASDAQ:AMRN)

Active Movers in Hot Line- T-Mobile US (NASDAQ:TMUS), Amarin Corporation (NASDAQ:AMRN)

Shares of T-Mobile US, Inc. (NASDAQ:TMUS) [Trend Analysis] runs in leading trade, it surging 2.18% to traded at $41.70. The firm has price volatility of 2.24% for a week and 2.31% for a month. Its beta stands at 1.09 times. T-Mobile US, Inc. (TMUS) revealed that the quarterly dividend on its 5.50% Mandatory Convertible Preferred Stock will be paid on June 15, 2016 to holders of record as of June 1, 2016. The dividend will be paid at a rate of $0.6875 per share of Preferred Stock. Narrow down four to firm performance, its weekly performance was 2.61% and monthly performance was 3.60%. The stock price of TMUS is moving up from its 20 days moving average with 3.90% and isolated positively from 50 days moving average with 6.77%.

Amarin Corporation plc (NASDAQ:AMRN) [Trend Analysis] luring active investment momentum, shares a gain 2.38% to $1.72. Amarin Corporation plc (AMRN) revealed that presentation of a poster at the annual meeting of the National Lipid Association (NLA) further characterizing the efficacy and safety of Vascepa (icosapent ethyl) in women with very high triglyceride levels.

The poster, titled “Icosapent Ethyl in Women With Very High Triglyceride Levels: Results From the MARINE Study,” was presented on May 20, 2016. Researchers observed that compared to placebo, Vascepa administered at 4 g/day significantly reduced triglyceride (TG), non-HDL-C, and total cholesterol (TC) levels without increasing LDL (“bad”) cholesterol in women with very high TG levels (≥500 and ≤2000 mg/dL). The analysis was led by Lori Mosca, MD, MPH, PhD, Professor of Medicine Emerita and Center Director of the American Heart Association Go Red for Women Research Network at Columbia University Medical Center, New York. The total volume of 1.35 Million shares held in the session was surprisingly higher than its average volume of 784.30 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -154.30%, and looking further price to next year’s EPS is 56.30%. While take a short look on price to sales ratio, that was 3.37.


About Devon Leftovich

Check Also

Stock Revamps on Eco Changes: Rigel Pharmaceuticals (NASDAQ:RIGL), JPMorgan Chase & Co. (NYSE:JPM)

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease …

Leave a Reply

Your email address will not be published. Required fields are marked *